Elekta

Elekta
Public (Nasdaq Stockholm: EKTA B)
Industry Oncology Neuroscience Radiation therapy Electronic medical record
Founder Lars Leksell
Headquarters Stockholm, Stockholm, Sweden
Number of locations
Stockholm, Crawley, Montréal, Québec, Atlanta, Georgia, Sunnyvale, California
Key people
Richard Hausmann, CEO[1]
Products Leksell Gamma Knife, Elekta Neuromag, Oncology Software (Mosaiq), Treatment Planning Software, Brachytherapy Products and systems for radiation therapy and surgery
Number of employees
3300
Website www.elekta.com

Elekta is a Swedish company that provides radiation therapy, radiosurgery, related equipment and clinical management for the treatment of cancer and brain disorders.

History

Elekta was founded in 1972 by the late Lars Leksell, Professor of Neurosurgery at the Karolinska Institute in Stockholm, Sweden. Since 1994, the company has been listed on the Nordic Exchange under the ticker EKTAb. Elekta was created to commercialize the development of the Leksell Stereotactic System, and Leksell Gamma Knife, which the professor had been researching since the late 1940s. Lars Leksell's son, Laurent, became chief executive officer of Elekta until 2005, and under his leadership the company expanded into a public medical technology group with more than 3,400 employees worldwide. In 2005 Tomas Puusepp became President and CEO of the company. The company trades only in Sweden, but nearly half the sales of the company's equipment are in the United States.[1] The company saw net sales of 10,839 SEK M (€1.16B as of January 2016) in the year 2014/15 [2]

Gammaknife

Acquisitions

References

  1. 1 2 Marcial, GG (2007-08-06). "Why Elekta May Be A Stockholm Standout". BusinessWeek. Retrieved 2016-07-28.
  2. "Elekta Annual Report 2014/15" (PDF). Elekta. Retrieved 15 January 2016.
  3. http://www.resonantmedical.com/en/news-events/special_downloads.php. Accessed: 2010-10-28. (Archived by WebCite at http://www.webcitation.org/5tonFuxOo)

External links

This article is issued from Wikipedia - version of the 11/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.